Front D, Ben-Haim S, Israel O, Epelbaum R, Haim N, Even-Sapir E, Kolodny G M, Robinson E
Department of Nuclear Medicine, Rambam Medical Center, Haifa, Israel.
Radiology. 1992 Feb;182(2):359-63. doi: 10.1148/radiology.182.2.1732950.
The negative predictive value (PV-) and positive predictive value (PV+) of gallium-67 scintigraphy and computed tomography (CT) were compared after treatment in 43 patients with Hodgkin disease and in 56 patients with non-Hodgkin lymphoma. The usefulness of these studies in predicting survival was also evaluated. In patients with Hodgkin disease, the PV- of Ga-67 scintigraphy was 0.84 and of CT was 0.88. The PV+ was 0.80 for Ga-67 studies and only 0.29 for CT. In patients with non-Hodgkin lymphoma, the PV- of Ga-67 scintigraphy was 0.84 and of CT was 0.80. The PV+ was 0.73 and 0.35, respectively. For both groups, the differences in disease-free survival between patients with negative and positive Ga-67 studies were significant (P less than .05 in Hodgkin disease and P less than .001 in non-Hodgkin lymphoma), but the differences were not significant for CT. These data show that, after treatment of patients with lymphoma, Ga-67 scintigraphy is a good predictor of clinical outcome and can be used beneficially in patient treatment.
对43例霍奇金病患者和56例非霍奇金淋巴瘤患者治疗后的镓67闪烁显像和计算机断层扫描（CT）的阴性预测值（PV-）和阳性预测值（PV+）进行了比较。还评估了这些检查在预测生存方面的有用性。在霍奇金病患者中，镓67闪烁显像的PV-为0.84，CT的PV-为0.88。镓67检查的PV+为0.80，而CT仅为0.29。在非霍奇金淋巴瘤患者中，镓67闪烁显像的PV-为0.84，CT的PV-为0.80。PV+分别为0.73和0.35。对于两组患者，镓67检查结果为阴性和阳性的患者在无病生存期方面的差异均具有显著性（霍奇金病患者P<0.05，非霍奇金淋巴瘤患者P<0.001），但CT检查结果的差异无显著性。这些数据表明，淋巴瘤患者治疗后，镓67闪烁显像对临床结果是一个很好的预测指标，可有益地用于患者治疗。
